Prostatype Genomics AB (PROGEN) — Cash Flow Reinvestment Rate
Latest as of June 2020:
0.06x
Prostatype Genomics AB (PROGEN) has a Cash Flow Reinvestment Rate of 0.06x as of June 2020, reinvesting Skr361.71K (capex Skr361.71K ) from operating cash flow of Skr5.63 Million. Explore Prostatype Genomics AB cash conversion from operations to assess how effectively this company generates cash.
Reinvestment Rate
0.06x
(Capex + Investments) / Operating CF
Total Reinvested
Skr361.71K
Capex + Investments
Operating Cash Flow
Skr5.63 Million
SEK
Capital Expenditures
Skr361.71K
SEK
Annual Cash Flow Reinvestment Rate for Prostatype Genomics AB (None–None)
Year-by-year capital reinvestment analysis for Prostatype Genomics AB. For live market cap and broader valuation context, see PROGEN stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow